So, I declined to use it, figuring the risk was too great. The drug in question was also very new to the market. This leads ...

An investigation published by The BMJ today raises new concerns over the landmark clinical trial (PLATO) that was used to gain worldwide approval for the anti-platelet drug ticagrelor (Brilinta in ...

[2] In 1998 only one drug in this class was available, a monoclonal antibody (abciximab) directed against the fibrinogen receptor on the platelet surface GP IIb/IIIa. A more recently approved drug ...

However, platelet reactivity to clopidogrel is variable and stent thrombosis can occur suddenly and unexpectedly in up to 3% of patients. Is responsiveness to clopidogrel an indicator of risk of ...

Rallybio estimated the drug’s commercial opportunity was greater than $1.6 billion. In FNAIT, the mother’s immune cells are ...

After dropping the FNAIT therapy, Rallybio will prioritise another candidate that is being investigated in complement-driven ...

Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicinesDesignation granted for warm autoimmune ...

The antiplatelet drug has been recommended for approval by the US regulator's cardiovascular and renal drugs advisory committee, which voted 10-1 in favour. The anticlotting agent would be the ...

Medically reviewed by Doru Paul, MD A low platelet count—also called thrombocytopenia—means your blood has fewer than 150,000 platelets per microliter. Platelets are cells that help your blood clot.

The average drug now costs more than US$1 billion to develop and takes more than a decade to reach the market 1. And for every success, there are nine drug candidates that fail clinical trials 2.

Febrile responses to platelet transfusions are common but some can be life-threatening and the cause of these reactions is largely unknown. In June 23 Lancet, Richard Phipps and colleagues from ...